

CURRICULUM VITAE
Claire Holmquist, PA-C

Practice Address: Darst Dermatology, PC
11301 Golf Links Drive North, Suite 203
Charlotte, NC 28277
cholmquist@darstderm.com

Site Affiliation: DJL Clinical Research, PLLC
431 N Wendover Rd
Charlotte, NC 28211

Education:

2016-2018	Masters in Physician Assistant Studies Wingate University Physician Assistant Program Wingate, North Carolina
2012-2016	Bachelor of Arts in Biology Nebraska Wesleyan University Lincoln, Nebraska

Healthcare Experience:

2019-Present	Darst Dermatology, PC Physician Assistant – Certified
2015	Celerion Clinical Research Clinical Conduct Associate

Certifications:

2017-Present	Advanced Cardiac Life Support (ACLS)
2017-Present	Basic Life Support (BLS)
2018-Present	National Commission on Certification of Physician Assistants

Professional Memberships:

2016-2017	Wingate University Physician Assistant Student Society, Class Historian
2016-Present	American Academy of Physician Assistants
2016-Present	North Carolina Academy of Physician Assistants
2018-Present	Metrolina Association of Physician Assistants

Clinical Research:

Sub-Investigator – Vanda Pharmaceuticals Inc- A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis (3101) (2019)

Sub-Investigator – Chemocentryx Protocol - A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. 2019

Sub-Investigator – Skintech - A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris. 2019

CURRICULUM VITAE
Claire Holmquist, PA-C

Sub-Investigator – Trevi Therapeutics: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) 2019

Sub-Investigator – Abbvie: A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis. 2019.

Sub-Investigator – Vanda Pharmaceuticals: A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis (3102). 2019

Sub-Investigator – Astrazeneca: A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

Sub-Investigator – Concert Pharmaceuticals: A Double-blind, Randomized, Placebo-controlled study to evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Sub-Investigator – Concert: A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Sub-Investigator – Concert: A Multicenter, Open-label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Sub-Investigator – Abbvie: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects with Moderate to Severe Psoriasis.

Sub-Investigator – Janssen: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.

Claire Holmquist PA-C
Signature

10-JAN-2023
Date